HbA1c-Bestimmung – ein neues Diagnosekriterium? / HbA1c – The new diagnostic criterion?

Zusammenfassung Entsprechend den aktuellen Leitlinien soll die Diagnosestellung des Typ 2 Diabetes mellitus (T2DM) in Deutschland anhand der Kriterien der American Diabetes Association (ADA) erfolgen, die sich an Kriterien der National Diabetes Data Group (NDDG) und der World Health Organisation (WHO) anlehnen. Zum Screening des T2DM wurde die Bestimmung des HbA1c-Wertes bislang allerdings von der ADA als diagnostischer Parameter abgelehnt, da er als nicht auseichend standardisiert und zu wenig sensitiv eingestuft wurde. In neueren Untersuchungen konnte allerdings eine gute Sensitivität und Spezifität des HbA1c-Wertes zur Diagnostik eines T2DM nachgewiesen werden, so dass zukünftig mit einer steigenden Bedeutung des HbA1c-Wert als Screening-Parameter des T2DM gerechnet werden kann. In der folgenden Übersicht soll deshalb die HbA1c-Bestimmung als mögliches Screeninginstrument und Prädiktor des Erkrankungsverlaufs näher erörtert werden. Abstract According to the current guidelines, in Germany type 2 diabetes mellitus (T2DM) is diagnosed by the criteria of the American Diabetes Association (ADA). Using HbA1c as a screening parameter of T2DM has not been accepted by the ADA until now because of insufficient standardisation and low sensitivity. Nevertheless, since recently published investigations could prove high sensitivity and specificity, HbA1c will gain more attention as a screening parameter. We discuss the meaning of HbA1c as a screening parameter for T2DM and as a predictor of disease progress.

• Publication year

  2009

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1515/JLM.2009.003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Utility of A1C for Diabetes Screening in the 1999-2004 NHANES Population

  2008cited by this paper
• A new look at screening and diagnosing diabetes mellitus.

  2008cited by this paper
• Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention Program

  2007cited by this paper
• Retinal Vascular Changes in Pre-Diabetes and Prehypertension

  2007cited by this paper
• Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose Tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)

  2007cited by this paper
• The combination of fasting plasma glucose and glycosylated hemoglobin predicts type 2 diabetes in Japanese workers.

  2007cited by this paper
• The prevalence of retinopathy in impaired glucose tolerance and recent‐onset diabetes in the Diabetes Prevention Program

  2007cited by this paper
• Short-term variability in measures of glycemia and implications for the classification of diabetes.

  2007cited by this paper
• Use of HbA1c in Predicting Progression to Diabetes in French Men and Women

  2006cited by this paper
• Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c.

  2006cited by this paper
• Estimate of biological variation of laboratory analytes based on the third national health and nutrition examination survey.

  2005cited by this paper
• Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study

  2005cited by this paper
• Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods.

  2005cited by this paper
• Utility of hemoglobin A1c in predicting diabetes risk

  2004cited by this paper
• Opportunistic screening for diabetes in routine clinical practice.

  2004cited by this paper
• Haemoglobin A1c – A Marker for Complications of Type 2 Diabetes: The Experience from the UK Prospective Diabetes Study (UKPDS)

  2003cited by this paper
• The spectrum of neuropathy in diabetes and impaired glucose tolerance

  2003cited by this paper
• Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

  2002cited by this paper
• Artificially low hemoglobin A1c caused by use of dapsone.

  2002cited by this paper
• HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP).

  2001cited by this paper
• Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population.

  2000cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria

  1999cited by this paper
• Undiagnosed NIDDM: Clinical and Public Health Issues

  1993cited by this paper
• The Response of GHb to Stepwise Plasma Glucose Change Over Time in Diabetic Patients

  1993cited by this paper
• Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis

  1992cited by this paper

• HbA1c als diagnostisches Kriterium des Diabetes mellitus: Ende einer alten oder Anfang einer neuen Kontroverse? / HbA1c for diagnosing diabetes: end of an old or beginning of a new controversy?

  2009cites this paper